Cargando…

Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies

BACKGROUND: A minority of HIV-1 infected individuals develop broad cross-neutralizing (BCN) plasma antibodies that are capable of neutralizing a spectrum of virus variants belonging to different HIV-1 clades. The aim of this study was to identify the targeted epitopes of an individual with BCN plasm...

Descripción completa

Detalles Bibliográficos
Autores principales: Dieltjens, Tessa, Heyndrickx, Leo, Willems, Betty, Gray, Elin, Van Nieuwenhove, Lies, Grupping, Katrijn, Vanham, Guido, Janssens, Wouter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801487/
https://www.ncbi.nlm.nih.gov/pubmed/20003438
http://dx.doi.org/10.1186/1742-4690-6-113
_version_ 1782175928407818240
author Dieltjens, Tessa
Heyndrickx, Leo
Willems, Betty
Gray, Elin
Van Nieuwenhove, Lies
Grupping, Katrijn
Vanham, Guido
Janssens, Wouter
author_facet Dieltjens, Tessa
Heyndrickx, Leo
Willems, Betty
Gray, Elin
Van Nieuwenhove, Lies
Grupping, Katrijn
Vanham, Guido
Janssens, Wouter
author_sort Dieltjens, Tessa
collection PubMed
description BACKGROUND: A minority of HIV-1 infected individuals develop broad cross-neutralizing (BCN) plasma antibodies that are capable of neutralizing a spectrum of virus variants belonging to different HIV-1 clades. The aim of this study was to identify the targeted epitopes of an individual with BCN plasma antibodies, referred to as ITM4, using peptide phage display. This study also aimed to use the selected mimotopes as tools to unravel the evolution of the antibody landscape and the viral envelope escape which may provide us with new insights for vaccine design. RESULTS: This study led us to identify ITM4 plasma antibodies directed to the 4E10 epitope located in the gp41 membrane-proximal external region (MPER). Analysis of antibody specificities revealed unusual immunogenic properties of the ITM4 viral envelope, as not only the V3 loop and the gp41 MPER but also the C1 and lentivirus lytic peptide 2 (LLP2) region seem to be targets of the immune system. The 4E10-like antibodies are consistently elicited during the 6-year follow up period. HIV-1 ITM4 pseudoviruses showed an increasing resistance over time to MPER monoclonal antibodies 4E10 and 2F5, although no changes are found in the critical positions of the epitope. Neutralization of COT6.15 (subtype C; 4E10-sensitive) pseudoviruses with alanine substitutions in the MPER region indicated an overlapping specificity of the 4E10 monoclonal antibody and the ITM4 follow up plasma. Moreover the 4E10-like antibodies of ITM4 contribute to the BCN capacity of the plasma. CONCLUSIONS: Using ITM4 BCN plasma and peptide phage display technology, we have identified a patient with 4E10-like BCN antibodies. Our results indicate that the elicited 4E10-like antibodies play a role in virus neutralization. The viral RNA was isolated at different time points and the ITM4 envelope sequence analysis of both early (4E10-sensitive) and late (4E10-resistant) viruses suggest that other regions in the envelope, outside the MPER region, contribute to the accessibility and sensitivity of the 4E10 epitope. Including ITM4 specific HIV-1 Env properties in vaccine strategies may be a promising approach.
format Text
id pubmed-2801487
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28014872010-01-05 Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies Dieltjens, Tessa Heyndrickx, Leo Willems, Betty Gray, Elin Van Nieuwenhove, Lies Grupping, Katrijn Vanham, Guido Janssens, Wouter Retrovirology Research BACKGROUND: A minority of HIV-1 infected individuals develop broad cross-neutralizing (BCN) plasma antibodies that are capable of neutralizing a spectrum of virus variants belonging to different HIV-1 clades. The aim of this study was to identify the targeted epitopes of an individual with BCN plasma antibodies, referred to as ITM4, using peptide phage display. This study also aimed to use the selected mimotopes as tools to unravel the evolution of the antibody landscape and the viral envelope escape which may provide us with new insights for vaccine design. RESULTS: This study led us to identify ITM4 plasma antibodies directed to the 4E10 epitope located in the gp41 membrane-proximal external region (MPER). Analysis of antibody specificities revealed unusual immunogenic properties of the ITM4 viral envelope, as not only the V3 loop and the gp41 MPER but also the C1 and lentivirus lytic peptide 2 (LLP2) region seem to be targets of the immune system. The 4E10-like antibodies are consistently elicited during the 6-year follow up period. HIV-1 ITM4 pseudoviruses showed an increasing resistance over time to MPER monoclonal antibodies 4E10 and 2F5, although no changes are found in the critical positions of the epitope. Neutralization of COT6.15 (subtype C; 4E10-sensitive) pseudoviruses with alanine substitutions in the MPER region indicated an overlapping specificity of the 4E10 monoclonal antibody and the ITM4 follow up plasma. Moreover the 4E10-like antibodies of ITM4 contribute to the BCN capacity of the plasma. CONCLUSIONS: Using ITM4 BCN plasma and peptide phage display technology, we have identified a patient with 4E10-like BCN antibodies. Our results indicate that the elicited 4E10-like antibodies play a role in virus neutralization. The viral RNA was isolated at different time points and the ITM4 envelope sequence analysis of both early (4E10-sensitive) and late (4E10-resistant) viruses suggest that other regions in the envelope, outside the MPER region, contribute to the accessibility and sensitivity of the 4E10 epitope. Including ITM4 specific HIV-1 Env properties in vaccine strategies may be a promising approach. BioMed Central 2009-12-14 /pmc/articles/PMC2801487/ /pubmed/20003438 http://dx.doi.org/10.1186/1742-4690-6-113 Text en Copyright ©2009 Dieltjens et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Dieltjens, Tessa
Heyndrickx, Leo
Willems, Betty
Gray, Elin
Van Nieuwenhove, Lies
Grupping, Katrijn
Vanham, Guido
Janssens, Wouter
Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
title Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
title_full Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
title_fullStr Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
title_full_unstemmed Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
title_short Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
title_sort evolution of antibody landscape and viral envelope escape in an hiv-1 crf02_ag infected patient with 4e10-like antibodies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801487/
https://www.ncbi.nlm.nih.gov/pubmed/20003438
http://dx.doi.org/10.1186/1742-4690-6-113
work_keys_str_mv AT dieltjenstessa evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies
AT heyndrickxleo evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies
AT willemsbetty evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies
AT grayelin evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies
AT vannieuwenhovelies evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies
AT gruppingkatrijn evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies
AT vanhamguido evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies
AT janssenswouter evolutionofantibodylandscapeandviralenvelopeescapeinanhiv1crf02aginfectedpatientwith4e10likeantibodies